MBXMBX Biosciences, Inc.
Is it safe?
Caution warranted: heavy debt (CCC) and big price swings.
Insiders were net sellers (-$24K, 90 days to Oct 8, 2026), selling is often routine.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -78% · now 25% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can MBX take a bad year?
The deepest fall in MBX's price history on file is −78%; it is 25% below its high today.
Worst drawdown on file · −25% today
- Cash runway
- 4.9 years
Cash runway · burning $21M a quarter at the current rate
- Annualised volatility
- 114%
Annualised volatility · three times the market's own swing
Details›
- Cash and short-term investments
- $419M
- EBITDA, trailing twelve months
- −$118M
- Operating profit, trailing twelve months
- −$118M
- Annualised volatilitytwo years of daily moves
- 114%
- Worst drawdown on file
- −78%
- Below its 52-week high
- 25%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry